Loading…
Aptevo Therapeutics Inc. is projected to decline to $3.73 by 2027, a -5% move from its current price of $3.94. APVO is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $3.81 | $3.94 | $4.08 | +0.01% |
| Jul 14 | $3.76 | $3.94 | $4.13 | +0.02% |
| Jul 15 | $3.72 | $3.94 | $4.18 | +0.04% |
| Jul 16 | $3.68 | $3.94 | $4.22 | +0.05% |
| Jul 17 | $3.66 | $3.94 | $4.25 | +0.06% |
| Jul 18 | $3.63 | $3.94 | $4.28 | +0.07% |
| Jul 19 | $3.61 | $3.94 | $4.31 | +0.08% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.61 | $3.94 | $4.31 | +0.08% |
| Week 2 | $3.48 | $3.95 | $4.48 | +0.17% |
| Week 3 | $3.38 | $3.95 | $4.61 | +0.25% |
| Week 4 | $3.31 | $3.95 | $4.73 | +0.34% |
| Week 5 | $3.24 | $3.96 | $4.83 | +0.42% |
| Week 6 | $3.18 | $3.96 | $4.93 | +0.51% |
| Week 7 | $3.13 | $3.96 | $5.02 | +0.59% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Aptevo Therapeutics Inc. is a clinical-stage research and development biotechnology company focused on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company uses its ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.
Its lead clinical blood cancer candidate is mipletamig, in Phase 1b/2 clinical trial for the treatment of acute myeloid leukemia. It also develops ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for the treatment of malignant pleural mesothelioma and other cancers; and APVO603, a preclinical dual agonist bispecific ADAPTIR candidate; APVO442, a preclinical bispecific candidate based on the ADAPTIR-FLEX platform technology for the treatment of multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate to treat prostate cancer. It has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527.
Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
The company operates in the Healthcare sector.
APVO trades at $3.94, with a market cap of $4.91M and a rank of 5333.
The near-term price outlook is neutral. For 2026, the forecast shows min $3.94, avg $3.94, max $5.07, ROI 0, sentiment NEUTRAL.
The year-by-year forecast shows a mixed path, with early years hovering around the current level and later years turning more bullish. Notable figures include 2027 ROI -5.8 with avg $3.71, 2028 ROI -1.9 with avg $3.87, 2029 ROI 25.5 with avg $4.95, 2030 ROI 28 with avg $5.04, and 2035 ROI 58.7 with avg $6.25. The forecast extends to 2040 (avg $6.81, ROI 73) and 2050 (avg $11.04, ROI 180.3), with sentiment upgrading to BULLISH in later years.
A major floor 22.0% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 33.0% above — a clean break opens room to run.
A major ceiling 70.9% above — clearing it would confirm fresh momentum.
Key APVO support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of APVO market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.27 | Sell | $4.19 | Sell |
| MA 10 | $4.38 | Sell | $4.34 | Sell |
| MA 20 | $4.54 | Sell | $4.49 | Sell |
| MA 50 | $4.75 | Sell | $4.82 | Sell |
| MA 100 | $5.03 | Sell | $11.50 | Sell |
| MA 200 | $12.19 | Sell | $1,309.30 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 29.03 | Buy |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -246.84 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.06 | Sell |
| ROC (12) | -14.90 | Sell |
| Bollinger %B (20,2) | -0.14 | Buy |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.34 | Sell |
| Awesome (5,34) | -0.43 | Sell |
| Ultimate (7,14,28) | 17.23 | Buy |
| Momentum (10) | -0.64 | Sell |
| Aroon Osc (25) | -96.00 | Sell |
| Hull MA (9) | 4.11 | Sell |
| ADX (14) | 15.60 | Neutral |
| ATR (14) | 0.11 | Info |
The 30-day technical picture is: sentiment NEUTRAL, RSI14 30, SMA50 $4.77, SMA200 $12.32, support $3.94, resistance $5.24. The 30-day range spans from $3.13 to $4.95, indicating limited upside within the near term.
Annualized volatility is 70%, underscoring substantial price variability over a year.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.94 | $3.94 | $5.07 | 0% | Neutral | |
| $2.90 | $3.73 | $5.10 | -5% | Neutral | |
| $2.90 | $3.85 | $5.51 | -2% | Neutral | |
| $3.60 | $4.93 | $7.30 | +25% | Bullish | |
| $3.58 | $5.03 | $7.67 | +28% | Bullish | |
| $3.20 | $4.61 | $7.20 | +17% | Neutral | |
| $3.19 | $4.70 | $7.51 | +19% | Neutral | |
| $2.92 | $4.39 | $7.16 | +12% | Neutral | |
| $3.28 | $5.05 | $8.38 | +28% | Bullish | |
| $3.98 | $6.24 | $10.54 | +58% | Bullish | |
| $3.96 | $6.79 | $12.31 | +72% | Bullish | |
| $5.52 | $11.09 | $22.31 | +182% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $3.94 | $3.94 | $4.77 | +0.00% |
| August 2026 | $3.44 | $4.09 | $5.00 | +3.76% |
| September 2026 | $3.32 | $3.98 | $4.94 | -2.56% |
| October 2026 | $3.21 | $3.88 | $4.87 | -2.63% |
| November 2026 | $3.28 | $3.98 | $5.04 | +2.63% |
| December 2026 | $3.24 | $3.97 | $5.07 | -0.40% |
Click any year to see its month-by-month APVO forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Aptevo Therapeutics Inc.'s 2026 outlook centres on $3.94, within a $3.94 to $5.07 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, APVO could reach as high as $5.10, with a base case around $3.73 and support toward $2.90 — roughly -5% from $3.94. Price action looks broadly range-bound.
Expect APVO to range from $2.90 to $5.51 through 2028. The $3.85 average target implies a -2% move from current prices. That is up +3% on the projected 2027 average. A consolidation phase looks the most probable path here.
The APVO price prediction for 2029 points to an average of $4.93 (low $3.60, high $7.30) — a potential gain of +25% on today's $3.94. Momentum favours further upside here.
In 2030, APVO is projected to trade between $3.58 and $7.67, averaging $5.03 — a potential gain of +28% from today's $3.94. That is up +2% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Aptevo Therapeutics Inc.'s 2031 outlook centres on $4.61, within a $3.20 to $7.20 range. That is -8% versus the projected 2030 average. That marks a +17% change versus current levels. Price action looks broadly range-bound.
By 2032, APVO could reach as high as $7.51, with a base case around $4.70 and support toward $3.19 — roughly +19% from $3.94. A consolidation phase looks the most probable path here.
Expect APVO to range from $2.92 to $7.16 through 2033. The $4.39 average target implies a +12% move from current prices. That is -6% versus the projected 2032 average. Price action looks broadly range-bound.
The APVO price prediction for 2034 points to an average of $5.05 (low $3.28, high $8.38) — a potential gain of +28% on today's $3.94. Buyers look set to stay in control over this stretch.
In 2035, APVO is projected to trade between $3.98 and $10.54, averaging $6.24 — a potential gain of +58% from today's $3.94. That is up +24% on the projected 2034 average. Momentum favours further upside here.
Aptevo Therapeutics Inc.'s 2040 outlook centres on $6.79, within a $3.96 to $12.31 range. That is up +9% on the projected 2035 average. That marks a +72% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, APVO could reach as high as $22.31, with a base case around $11.09 and support toward $5.52 — roughly +182% from $3.94. Momentum favours further upside here.
Investing $1,000 in APVO today (≈ 253.807107 APVO) could be worth
$2,815.78
+$1,815.78 (+182%) by 2050 · US Dollar
Based on the average projected APVO price of $11.09 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in APVOwould be worth at today's price.
$1,000 invested in APVO on Jul 10, 2025 (≈ 18.456995 APVO) would be worth
$72.72
-$927.28 (-92.7%) today · 0.07× · US Dollar
Based on a APVO entry price of $54.18 vs. today's $3.94.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.47 | $881.43 | -11.9% |
| 1 month ago | $4.72 | $834.75 | -16.5% |
| 3 months ago | $4.44 | $887.39 | -11.3% |
| 6 months ago | $8.97 | $439.24 | -56.1% |
| 1 year ago | $54.18 | $72.72 | -92.7% |
| All time (5.0y) ago | $11,504,750 | $0 | -100.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our APVO forecast.
Our base-case forecast reaches $7.90 around 2050.
Implied market cap at $7.90: $9.84M
The multi-year forecast shows a gradual rise in the average price with an improving sentiment in later years. In 2029 the avg is $4.95 with ROI 25.5 and sentiment BULLISH, rising to 2030 avg $5.04 with ROI 28 and BULLISH, and to 2035 avg $6.25 with ROI 58.7 and BULLISH. The trajectory continues into 2040 with avg $6.81 and ROI 73, and culminates in 2050 with avg $11.04, max $22.47, ROI 180.3, sentiment BULLISH.
Early years show more modest or neutral results (e.g., 2026 avg $3.94 ROI 0, 2027 avg $3.71 ROI -5.8, 2028 avg $3.87 ROI -1.9), while later years reflect stronger upside potential.
These figures are estimates, not guarantees, and actual results may differ. The forecast implies potential upside over the long term but also includes periods of flat or negative returns in the near term. Potential drivers include clinical trial progress and collaborations, while risks include clinical outcomes and market dynamics.
Tap a question to reveal the answer.
In 2030 the forecast shows an average price of $5.04, with a range from $3.56 to $7.74. The ROI is 28%, and sentiment is BULLISH.
The near-term forecast for 2026 is NEUTRAL with ROI 0. In 2027 and 2028 the ROI is -5.8% and -1.9% respectively, with NEUTRAL sentiment. The outlook turns bullish in 2029 (ROI 25.5%) and remains bullish through later years, with 2050 showing ROI 180.3% and sentiment BULLISH.
Yes. The forecast shows a max of $10.66 in 2035, with higher maxima in later years: $12.49 in 2040 and $22.47 in 2050.
RSI 14 is 30, indicating neutral momentum. The 50-day simple moving average is $4.77 and the 200-day simple moving average is $12.32. Current price is $3.94, with support at $3.94 and resistance at $5.24. The 30-day price range is $3.13 to $4.95, and annualized volatility is 70%.
Current price is $3.94 and market cap is $4.91M. The rank is 5333.
Aptevo Therapeutics Inc. Community Discussion
0Share your Aptevo Therapeutics Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.